bioRxivImmunologyPreprint
An endogenous glucocorticoid-cytokine signaling circuit promotes CD8+ T cell dysfunction in the tumor microenvironment
N. Acharya, A. Madi, H. Zhang, M. Klapholz, E. Christian, K. O. Dixon, G. Fell, K. Tooley, D. Mangani, J. Xia, M. Singer, D. Neuberg, O. Rozenblatt-Rosen, A. Regev, V. K. Kuchroo, A. C. Anderson
Abstract
Identifying signals in the tumor microenvironment (TME) that promote CD8+ T cell dysfunction can inform improved therapeutic approaches for cancer. Here, we identify that Nr3c1, the gene encoding the glucocorticoid receptor (GR), is highly expressed in dysfunctional CD8+ tumor-infiltrating lymphocytes (TILs). The GR transactivates expression of multiple checkpoint receptors and loss of GR in CD8+ T cells limits dysfunctional phenotype in CD8+ TILs resulting in improved tumor growth control. We show that glucocorticoids can be produced in the TME and that they co-operate with the immunosuppressive cytokine IL-27 to promote the dysfunction gene program in CD8+ T cells. The presence of the glucocorticoid + IL27 signature in CD8+ TILs correlates with failure to respond to checkpoint blockade in melanoma patients, highlighting the relevance of this immunoregulatory glucocorticoid-cytokine circuit in tumor tissue.
- organism: human
- assay: bulk RNA-seq
- research focus: host-pathogen & immune response
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Glucocorticoid receptor and RUNX transcription factors cooperatively drive CD8 T cell dysfunction in human cancer
Christopher J. Ward, Soura Chakraborty, … Bidesh Mahata·Cell ReportsPeer-reviewed·May 1, 2026
- Glucocorticoids unleash immune-dependent melanoma control through inhibition of the GARP/TGF-β axis
Charles H. Earnshaw, Poppy Dunn, … Santiago Zelenay·bioRxiv·Jul 24, 2025
- Glucocorticoid receptor activation reprograms NK cells to drive AREG-mediated immunosuppression in skin cancer
- Tumour-derived glucocorticoids amplify ROR1 and are exploited with glucocorticoid-resistant ROR1 CAR-T cells
Marc Philipp Schauer, Justus Weber, … Michael Hudecek·bioRxiv·Jan 28, 2025
- Systemic immune dysfunction in cancer patients driven by IL6 and IL8 induction of an inhibitory receptor module in peripheral CD8+ T cells
A. Somasundaram, A. R. Cillo, … D. A. A. Vignali·bioRxiv·May 6, 2020
- Lack of Bcl6 promotes anti-tumor immunity by activating glycolysis to rescue CD8 T cell function
Fangkun Luan, Yunqiao Li, … David A. Nemazee·bioRxiv·Apr 1, 2025